Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions

Sten Myrehaug, Arjun Sahgal, Suzanne M. Russo, Simon S. Lo, Lauren M. Rosati, Nina A. Mayr, Michael Lock, William Small, Jennifer A. Dorth, Rodney J. Ellis, Bin S. Teh, Joseph M. Herman

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

ABSTRACT: Despite advances in surgical, medical, and radiation therapy for pancreatic cancer, the prognosis remains poor. At this time, the only chance for long-term survival is surgical resection. More challenging is the optimal management of unresectable locally advanced pancreatic cancer, which has historically been treated with concurrent chemoradiation or chemotherapy alone. However, the survival and local control benefit of conventional radiotherapy in addition to chemotherapy was unclear. More recently, stereotactic body radiotherapy (SBRT) is emerging as a viable approach to maximizing local tumor control with a tolerable side effect profile. SBRT achieves sharp dose fall-off facilitating safe delivery of highly focused radiation to the tumor over 1-5 days. Although the optimal regimen of pancreas SBRT has not yet been established, its short treatment course limits the delay of additional. Future directions involve prospective study of pancreas SBRT and exploration of biomarkers and imaging technology in order to adopt a personalized management paradigm.

Original languageEnglish (US)
Pages (from-to)523-530
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume16
Issue number5
DOIs
StatePublished - May 3 2016

Fingerprint

Radiosurgery
Pancreatic Neoplasms
Pancreas
Radiotherapy
Drug Therapy
Neoplasms
Biomarkers
Prospective Studies
Radiation
Technology
Direction compound
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Myrehaug, S., Sahgal, A., Russo, S. M., Lo, S. S., Rosati, L. M., Mayr, N. A., ... Herman, J. M. (2016). Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Review of Anticancer Therapy, 16(5), 523-530. https://doi.org/10.1586/14737140.2016.1168698
Myrehaug, Sten ; Sahgal, Arjun ; Russo, Suzanne M. ; Lo, Simon S. ; Rosati, Lauren M. ; Mayr, Nina A. ; Lock, Michael ; Small, William ; Dorth, Jennifer A. ; Ellis, Rodney J. ; Teh, Bin S. ; Herman, Joseph M. / Stereotactic body radiotherapy for pancreatic cancer : recent progress and future directions. In: Expert Review of Anticancer Therapy. 2016 ; Vol. 16, No. 5. pp. 523-530.
@article{a0269ec678284a31b2f3274981b1388f,
title = "Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions",
abstract = "ABSTRACT: Despite advances in surgical, medical, and radiation therapy for pancreatic cancer, the prognosis remains poor. At this time, the only chance for long-term survival is surgical resection. More challenging is the optimal management of unresectable locally advanced pancreatic cancer, which has historically been treated with concurrent chemoradiation or chemotherapy alone. However, the survival and local control benefit of conventional radiotherapy in addition to chemotherapy was unclear. More recently, stereotactic body radiotherapy (SBRT) is emerging as a viable approach to maximizing local tumor control with a tolerable side effect profile. SBRT achieves sharp dose fall-off facilitating safe delivery of highly focused radiation to the tumor over 1-5 days. Although the optimal regimen of pancreas SBRT has not yet been established, its short treatment course limits the delay of additional. Future directions involve prospective study of pancreas SBRT and exploration of biomarkers and imaging technology in order to adopt a personalized management paradigm.",
author = "Sten Myrehaug and Arjun Sahgal and Russo, {Suzanne M.} and Lo, {Simon S.} and Rosati, {Lauren M.} and Mayr, {Nina A.} and Michael Lock and William Small and Dorth, {Jennifer A.} and Ellis, {Rodney J.} and Teh, {Bin S.} and Herman, {Joseph M.}",
year = "2016",
month = "5",
day = "3",
doi = "10.1586/14737140.2016.1168698",
language = "English (US)",
volume = "16",
pages = "523--530",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

Myrehaug, S, Sahgal, A, Russo, SM, Lo, SS, Rosati, LM, Mayr, NA, Lock, M, Small, W, Dorth, JA, Ellis, RJ, Teh, BS & Herman, JM 2016, 'Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions', Expert Review of Anticancer Therapy, vol. 16, no. 5, pp. 523-530. https://doi.org/10.1586/14737140.2016.1168698

Stereotactic body radiotherapy for pancreatic cancer : recent progress and future directions. / Myrehaug, Sten; Sahgal, Arjun; Russo, Suzanne M.; Lo, Simon S.; Rosati, Lauren M.; Mayr, Nina A.; Lock, Michael; Small, William; Dorth, Jennifer A.; Ellis, Rodney J.; Teh, Bin S.; Herman, Joseph M.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 5, 03.05.2016, p. 523-530.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Stereotactic body radiotherapy for pancreatic cancer

T2 - recent progress and future directions

AU - Myrehaug, Sten

AU - Sahgal, Arjun

AU - Russo, Suzanne M.

AU - Lo, Simon S.

AU - Rosati, Lauren M.

AU - Mayr, Nina A.

AU - Lock, Michael

AU - Small, William

AU - Dorth, Jennifer A.

AU - Ellis, Rodney J.

AU - Teh, Bin S.

AU - Herman, Joseph M.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - ABSTRACT: Despite advances in surgical, medical, and radiation therapy for pancreatic cancer, the prognosis remains poor. At this time, the only chance for long-term survival is surgical resection. More challenging is the optimal management of unresectable locally advanced pancreatic cancer, which has historically been treated with concurrent chemoradiation or chemotherapy alone. However, the survival and local control benefit of conventional radiotherapy in addition to chemotherapy was unclear. More recently, stereotactic body radiotherapy (SBRT) is emerging as a viable approach to maximizing local tumor control with a tolerable side effect profile. SBRT achieves sharp dose fall-off facilitating safe delivery of highly focused radiation to the tumor over 1-5 days. Although the optimal regimen of pancreas SBRT has not yet been established, its short treatment course limits the delay of additional. Future directions involve prospective study of pancreas SBRT and exploration of biomarkers and imaging technology in order to adopt a personalized management paradigm.

AB - ABSTRACT: Despite advances in surgical, medical, and radiation therapy for pancreatic cancer, the prognosis remains poor. At this time, the only chance for long-term survival is surgical resection. More challenging is the optimal management of unresectable locally advanced pancreatic cancer, which has historically been treated with concurrent chemoradiation or chemotherapy alone. However, the survival and local control benefit of conventional radiotherapy in addition to chemotherapy was unclear. More recently, stereotactic body radiotherapy (SBRT) is emerging as a viable approach to maximizing local tumor control with a tolerable side effect profile. SBRT achieves sharp dose fall-off facilitating safe delivery of highly focused radiation to the tumor over 1-5 days. Although the optimal regimen of pancreas SBRT has not yet been established, its short treatment course limits the delay of additional. Future directions involve prospective study of pancreas SBRT and exploration of biomarkers and imaging technology in order to adopt a personalized management paradigm.

UR - http://www.scopus.com/inward/record.url?scp=84963853719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963853719&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1168698

DO - 10.1586/14737140.2016.1168698

M3 - Review article

C2 - 26999329

AN - SCOPUS:84963853719

VL - 16

SP - 523

EP - 530

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -